Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma (Q34426949)

2 August 2017

Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma (English)

1 reference

2 August 2017

1 reference

1 reference

1 reference

11

Markus Vähä-Koskela

1 reference

2 August 2017

12

Akseli Hemminki

1 reference

2 August 2017

9

Anna Kanerva

1 reference

2 August 2017

Mikko Siurala

1

1 reference

2 August 2017

Simona Bramante

2

1 reference

2 August 2017

Lotta Vassilev

3

1 reference

2 August 2017

Mari Hirvinen

4

1 reference

2 August 2017

Suvi Parviainen

5

1 reference

2 August 2017

Siri Tähtinen

6

1 reference

2 August 2017

Kilian Guse

7

1 reference

2 August 2017

Vincenzo Cerullo

8

1 reference

2 August 2017

Anja Kipar

10

1 reference

2 August 2017

language of work or name

English

0 references

publication date

3 July 2014

1 reference

International Journal of Cancer

2 August 2017

1 reference

2 August 2017

136

1 reference

2 August 2017

945-954

1 reference

2 August 2017

4

1 reference

Soft-tissue sarcomas in adults

2 August 2017

1 reference

The molecular biology of soft-tissue sarcomas and current trends in therapy

21 January 2018

1 reference

Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.

21 January 2018

1 reference

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

21 January 2018

1 reference

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

The secret ally: immunostimulation by anticancer drugs

21 January 2018

1 reference

Immune parameters affecting the efficacy of chemotherapeutic regimens

21 January 2018

1 reference

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

21 January 2018

1 reference

Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments

21 January 2018

1 reference

Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer

21 January 2018

1 reference

Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation

21 January 2018

1 reference

Intelligent design: combination therapy with oncolytic viruses

21 January 2018

1 reference

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

21 January 2018

1 reference

21 January 2018

1 reference

Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

21 January 2018

1 reference

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients

21 January 2018

1 reference

Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus

21 January 2018

1 reference

Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus

21 January 2018

1 reference

Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients

21 January 2018

1 reference

Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans

21 January 2018

1 reference

Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer

21 January 2018

1 reference

Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma

21 January 2018

1 reference

Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.

21 January 2018

1 reference

Chapter three--Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds

21 January 2018

1 reference

The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas

21 January 2018

1 reference

Enhanced killing of therapy-induced senescent tumor cells by oncolytic measles vaccine viruses

21 January 2018

1 reference

Enhanced Adenovirus Infection of Melanoma Cells by Fiber-Modification: Incorporation of RGD Peptide or Ad5/3 Chimerism

21 January 2018

1 reference

Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer

21 January 2018

1 reference

Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment

21 January 2018

1 reference

Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin

21 January 2018

1 reference

[(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer

21 January 2018

1 reference

Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer

21 January 2018

1 reference

Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer

21 January 2018

1 reference

Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment

21 January 2018

1 reference

Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients

21 January 2018

1 reference

Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors

21 January 2018

1 reference

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.29048

1 reference

2 August 2017

1 reference